Loss of FAM46C Promotes Cell Survival in Myeloma
©2017 American Association for Cancer Research..
FAM46C is one of the most recurrently mutated genes in multiple myeloma; however its role in disease pathogenesis has not been determined. Here we demonstrate that wild-type (WT) FAM46C overexpression induces substantial cytotoxicity in multiple myeloma cells. In contrast, FAM46C mutations found in multiple myeloma patients abrogate this cytotoxicity, indicating a survival advantage conferred by the FAM46C mutant phenotype. WT FAM46C overexpression downregulated IRF4, CEBPB, and MYC and upregulated immunoglobulin (Ig) light chain and HSPA5/BIP Furthermore, pathway analysis suggests that enforced FAM46C expression activated the unfolded protein response pathway and induced mitochondrial dysfunction. CRISPR-mediated depletion of endogenous FAM46C enhanced multiple myeloma cell growth, decreased Ig light chain and HSPA5/BIP expression, activated ERK and antiapoptotic signaling, and conferred relative resistance to dexamethasone and lenalidomide treatments. Genes altered in FAM46C-depleted cells were enriched for signaling pathways regulating estrogen, glucocorticoid, B-cell receptor signaling, and ATM signaling. Together these results implicate FAM46C in myeloma cell growth and survival and identify FAM46C mutation as a contributor to myeloma pathogenesis and disease progression via perturbation in plasma cell differentiation and endoplasmic reticulum homeostasis. Cancer Res; 77(16); 4317-27. ©2017 AACR.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:77 |
|---|---|
| Enthalten in: |
Cancer research - 77(2017), 16 vom: 15. Aug., Seite 4317-4327 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhu, Yuan Xiao [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
EC 2.7.7.- |
|---|
| Anmerkungen: |
Date Completed 29.09.2017 Date Revised 30.03.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1158/0008-5472.CAN-16-3011 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM272982717 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM272982717 | ||
| 003 | DE-627 | ||
| 005 | 20231225000048.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/0008-5472.CAN-16-3011 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0909.xml |
| 035 | |a (DE-627)NLM272982717 | ||
| 035 | |a (NLM)28619709 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhu, Yuan Xiao |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Loss of FAM46C Promotes Cell Survival in Myeloma |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.09.2017 | ||
| 500 | |a Date Revised 30.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a ©2017 American Association for Cancer Research. | ||
| 520 | |a FAM46C is one of the most recurrently mutated genes in multiple myeloma; however its role in disease pathogenesis has not been determined. Here we demonstrate that wild-type (WT) FAM46C overexpression induces substantial cytotoxicity in multiple myeloma cells. In contrast, FAM46C mutations found in multiple myeloma patients abrogate this cytotoxicity, indicating a survival advantage conferred by the FAM46C mutant phenotype. WT FAM46C overexpression downregulated IRF4, CEBPB, and MYC and upregulated immunoglobulin (Ig) light chain and HSPA5/BIP Furthermore, pathway analysis suggests that enforced FAM46C expression activated the unfolded protein response pathway and induced mitochondrial dysfunction. CRISPR-mediated depletion of endogenous FAM46C enhanced multiple myeloma cell growth, decreased Ig light chain and HSPA5/BIP expression, activated ERK and antiapoptotic signaling, and conferred relative resistance to dexamethasone and lenalidomide treatments. Genes altered in FAM46C-depleted cells were enriched for signaling pathways regulating estrogen, glucocorticoid, B-cell receptor signaling, and ATM signaling. Together these results implicate FAM46C in myeloma cell growth and survival and identify FAM46C mutation as a contributor to myeloma pathogenesis and disease progression via perturbation in plasma cell differentiation and endoplasmic reticulum homeostasis. Cancer Res; 77(16); 4317-27. ©2017 AACR | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Endoplasmic Reticulum Chaperone BiP |2 NLM | |
| 650 | 7 | |a HSPA5 protein, human |2 NLM | |
| 650 | 7 | |a Proteins |2 NLM | |
| 650 | 7 | |a Nucleotidyltransferases |2 NLM | |
| 650 | 7 | |a EC 2.7.7.- |2 NLM | |
| 650 | 7 | |a TENT5C protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.7.- |2 NLM | |
| 700 | 1 | |a Shi, Chang-Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Bruins, Laura A |e verfasserin |4 aut | |
| 700 | 1 | |a Jedlowski, Patrick |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xuewei |e verfasserin |4 aut | |
| 700 | 1 | |a Kortüm, K Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Moulun |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmann, Jonathan M |e verfasserin |4 aut | |
| 700 | 1 | |a Braggio, Esteban |e verfasserin |4 aut | |
| 700 | 1 | |a Stewart, A Keith |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer research |d 1945 |g 77(2017), 16 vom: 15. Aug., Seite 4317-4327 |w (DE-627)NLM000001740 |x 1538-7445 |7 nnns |
| 773 | 1 | 8 | |g volume:77 |g year:2017 |g number:16 |g day:15 |g month:08 |g pages:4317-4327 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1158/0008-5472.CAN-16-3011 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 77 |j 2017 |e 16 |b 15 |c 08 |h 4317-4327 | ||